Dinesh Khanna, MD
Enriched profileProfessor of Medicine (Frederick G.L. Huetwell Professor of Rheumatology); Director, University of Michigan Scleroderma Program · University of Michigan
Dinesh Khanna is Professor of Medicine (Frederick G.L. Huetwell Professor of Rheumatology); Director, University of Michigan Scleroderma Program at University of Michigan. OpenAlex indexes 847 publications with 59,350 citations (h-index 103); ClinicalTrials.gov lists 13 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 1% of Rheumatology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 13 Oct 2026
Dinesh Khanna, MD, is Professor of Medicine (Frederick G.L. Huetwell Professor of Rheumatology) at University of Michigan / Michigan Medicine, Division of Rheumatology, Ann Arbor, MI. The public record shows 847 publications with 59,350 citations (h-index 103), centered on Rheumatoid Arthritis, Lupus (SLE). It also documents an investigator role on 13 registered clinical trials, industry payments reported by 34 companies, 7 NIH-funded awards (2011–2026).
- Most recent indexed publication: 2026 · Rheumatology (Oxford, England)
- Top research focus: Rheumatoid Arthritis
- 13 registered trials on ClinicalTrials.gov
- Open Payments reporting from 34 companies
Generated from the cited public record · current as of 13 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 113 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 13 Oct 2026
Listed as an investigator on 13 registered studies on ClinicalTrials.gov. The most recent:
- Systemic Sclerosis DIet for GastrointESTinal Symptoms
Sponsor: University of Michigan
- PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis
Sponsor: University of Massachusetts, Worcester
- The Apollo Device in Systemic Sclerosis for the Management of fatiguE, Raynaud Phenomenon and qualiTy of Life
Sponsor: Robyn T. Domsic, MD, MPH
Industry payments
Updated 13 Oct 2026
34 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- AstraZeneca UK LimitedProgram year202525 payments$101,957openpaymentsdata.cms.gov ↗
- ARGENX US, INC.Program year202522 payments$101,930openpaymentsdata.cms.gov ↗
- Boehringer Ingelheim International GmbHProgram year202516 payments$28,242openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
35.2%Corticosteroid24.8%Prednisone100%Part D<11 patientsH2 blocker10.5%Famotidine100%Part D<11 patientsGenitourinary & hormones
18.1%Phosphodiesterase 5 Inhibitor18.1%Sildenafil Citrate100%Part D<11 patientsCancer & immunology
16.2%Interleukin-6 Receptor Antagonist16.2%Actemra Actpen100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 13 Oct 2026
7 NIH research awards on record, funded 2011–2026 per NIH RePORTER. The latest:
- Role of the Hippo pathway in scleroderma pathogenesis
University of Michigan at Ann Arbor
FY2026$601,644R01AI183620 - Role of the Hippo pathway in scleroderma pathogenesis
University of Michigan at Ann Arbor
FY2025$583,594R01AI183620 - Planning for a Multisite Efficacy Trial of Upper Extremity Telerehabilitation for Systemic Sclerosis
University of Michigan at Ann Arbor
FY2025$99,871R34AR082551
Publications
Updated 13 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- The clinical utility of telangiectasia quantification as markers of vascular disease progression in systemic sclerosis.
Rheumatology (Oxford, England)
Article2026 - Expert Perspectives: Defining and Managing Progressive Pulmonary Fibrosis in Systemic Sclerosis.
Arthritis & rheumatology (Hoboken, N.J.)
Review2026 - Discordance Between Patient and Physician Global Assessments in Early Systemic Sclerosis.
Arthritis care & research
Article2026 - Prioritizing Therapeutic Targets for Interstitial Lung Disease: A Causal Mediation Analysis.
Research square
Article2026
Online presence
Updated 13 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Mentions by others
where others cite or feature them- YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 13 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →uofmhealth.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →uofmhealth.org ↗
Editorial & leadership roles
journal and society appointments- Immediate past president
Scleroderma Clinical Trials Consortium (SCTC)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →sclerodermaclinicaltrialsconsortium.org ↗
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →rheumatologyacademy.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →annarbor.com ↗
Secondary affiliations
appointments beyond the home institution- Center Member
Institute for Healthcare Policy and Innovation (IHPI), University of Michigan
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ihpi.umich.edu ↗
Media & interviews
press, podcasts and appearances- Video interview on systemic sclerosis management
Scleroderma Video
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →sclerodermavideo.com ↗ - Video/audio education content host profile
ReachMD (medical CME platform)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →reachmd.com ↗ - Featured expert
Michigan Medicine Health Lab news feature on rare scleroderma organ damage
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →michiganmedicine.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Max Wicha, MD
University of Michigan
Eva Feldman, MD
University of Michigan
Matthias Kretzler, MD
University of Michigan
Theodore Lawrence, MD
University of Michigan
Marc Hochberg, MD
University of Maryland School of Medicine
Michelle Petri, MD
Johns Hopkins University School of Medicine
Matthew Liang, MD
Brigham and Women's Hospital
Eric Matteson, MD
Mayo Clinic